Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine and Immunotherapy in Advanced Renal Cell Carcinoma
NCT00311467Phase 3Terminated
- Sponsor
- Central European Cooperative Oncology Group
- Start
- Mar 2004
- Primary completion
- May 2007
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine in renal cell carcinoma (RCC), sponsored by Central European Cooperative Oncology Group. Started Mar 2004; status: terminated.
02
Drugs
capecitabine
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00311467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00311467.